{
  "id": 6274580,
  "title": "Sun Pharma gets ratings boost from Moody's, S&P over ₹11.75-billion Organon & Co acquisition bid",
  "url": "https://urgent.news/2026/09/08/sun-pharma-gets-ratings-boost-from-moodys-s-p-over-11-75-billion",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-08T11:15:45.000Z",
  "source": {
    "name": "Hindu BusinessLine",
    "slug": "hindu-businessline",
    "url": "https://www.thehindubusinessline.com/markets/sun-pharma-gets-ratings-boost-from-moodys-sp-over-1175-billion-organon-co-acquisition-bid/article71442285.ece"
  },
  "original_language": "en",
  "account": "Rating agencies Moody's and S&P Global assigned investment-grade ratings to Sun Pharmaceutical Industries, India's largest pharmaceutical company, following its proposed $11.75 billion acquisition of US-based Organon & Co. S&P Global granted the company a long-term issuer credit rating of BBB+, while Moody's assigned a Baa1 rating. Both agencies maintain a stable outlook for Sun Pharma. The acquisition is expected to close by March 2027, subject to regulatory approvals. S&P believes the merger will nearly double Sun Pharma's revenue base to approximately $1.3 trillion by FY28, with Organon contributing 40-45% of the group's EBITDA post-acquisition. The acquisition will strengthen Sun Pharma's scale, geographic reach, and growth platforms, particularly in women's health and biosimilars. S&P estimates Sun Pharma's revenue will reach around $1.3 trillion by fiscal 2028, up from $645 billion in fiscal 2027 (excluding Organon). Organon's presence in markets like China and Korea will allow Sun Pharma to cross-sell its products, as the company currently has limited presence in these countries. Moody's noted that Sun Pharma has secured a $12 billion committed acquisition bridge loan from international banks, with the company holding approximately $3.6 billion in cash as of March 31, 2026.",
  "summary": "S&P Global Ratings assigned a preliminary 'BBB+' long-term issuer credit rating, while Moody's Ratings assigned a 'Baa1' long-term issuer rating to the Indian pharmaceutical major",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}